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F eshly isolated human Langerhans cells (LC) express two 
f \ms of FcyRII: a membrane-associated form detected by 
o onodonal antibody (MoAb) anti-CD32, which recognize 
m extracytoplasmic epitope of the molecule, and a soluble 
an I · · d b secreted form, w JOse eXlste.nce IS . suggeste y rever~e 
transcriptase-polymerase cham reactlon (RT-PCR) expen-
ments. Indeed, RT -PCR performed on total LC RNA reveals 
the presence of two FcyRIlA mR~A, one encoding the 
FCyRIIA with a transmembrane regIOn (membranous form) 
and the other without this region (soluble form). Densitome-
try studies performed on the two PCR products reveal that 
the ratio between the membranous form and the soluble 
ecreted form is about 1.5. LC maintained in culture for ~4-48 h lose the major part of their membrane FcyRII ex-
ress ion (shown by flow cytometry) and release soluble 
tcyRIl molecules (revealed by dot-blot assay), but ~aintain 
the same ratio of the two FcyRIIA mRNA. The dlsappear-
T hree classes of receptors for the Fc fragment of IgG (FcyR) have been described on human cells: FcyRIj CD64, FcyRlljCD32, and FcyRIIIjCD16 [1]. Molecular cloning of their cDNA has demonstrated that they all three belong to the immunoglobulin su-
erEamily and are integral membrane proteins with an amino-ter-~inal extracellular portion containing two or three immunoglobu-
lin-related domains, a single-membrane-spanning domain, and a 
carboxy-terminal cytoplasmic domain of variable length. There is, 
however, one exception, the neutrophil FcyRIll, which was found 
to be anchored in the membrane via a glycosyl-phosphatidylinositol 
moiety. These three F~yR Ca!l be distinguished on th~ basis of their 
molecular weight, thelr affimty for human and mouse Immunoglob-
ulin subclasses, their reactivity with specific monoclonal antibodies 
(MoAb) and their cell distribution (reviewed in [2]). FcyRI is ex-
pressed only on mononuclear phagocytes, whereas FcyRIl is present 
on a much broader range of cells, including not only mononuclear 
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ance of the membrane-associated FcyRII may be explained 
either by modification of its recycling pathway or by proteo-
lytic cleavage of the receptor at the cell surface. Thus, soluble 
FcyRII molecules generated during LC culture may result 
from proteolytic cleavage of the cell-surface receptor and/or 
secretion of a soluble form derived from the translation of an 
alternate spliced mRNA. Interestingly, addition of TNF-a 
(10 ng/ml) to the culture medium i) maintains the expression 
of the membranous form, which can be detected on the LC 
surface at the same level as on freshly isolated LC, and ii) 
reverses the ratio (to 0.6) of the two FcyRII mRNA, the 
mRNA encoding the soluble form becoming predominant. 
Thus, TNF-a seems to modify the expression of the FcyRII 
at the mRNA level, favoring the secretion of soluble FcyRIl 
molecules, and changes the fate of the membranous FcyRII.] 
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phagocy~es but also granulocytes, platelets, and B lymphocytes. 
FcyRIlI IS expressed on macrophages, granulocytes, and killerjna-
~ra.1 ki~ler (KjNK) cel.ls. Thus, these three FcyR are expressed on 
dlstmctlve but overlappmg populations of cells and various combina-
tions can be noted. Although macrophages bear all three FeyR, 
monocytes and granulocytes express only two of the three FeyR: 
FcyRI and FcyRIl in the case of monocytes, FcyRIl and FcyRIIl in 
the Case of granulocytes. KINK cells bear only FcyRIll, whereas 
platelets and B lymphocytes only express FcyRll. 
HUMAN EPIDERMAL LANGERHANS CELLS EXPRESS 
ONLY THE FCyRlljCD32 CLASS OF RECEPTORS 
Since the work of Sting 1 et al [3] in 1977 , human epidermal Langer-
hans cells (LC) are known to possess FcrR. This characteristic was 
demonstrated by a rosette technique, using bovine erythrocytes sen-
sitized by rabbit IgG anti-bovine erythrocytes. However, at this 
time, the molecular and functional heterogeneity of the FcyR was 
unknown. Recently, using anti-FcyRI, anti-FcyRIl, and anti-
FcyRIll MoAb, we have investigated by immunolabeling tech-
niques and rosette assays the classes of FcyR expressed by normal 
human LC [4]. First evidence that LC express FcyRll came from 
experiments in which murine IgG i-coated erythrocytes were ob-
served to form rosettes with LC, but not with LC that had been 
pre-incubated with an anti-FC)'RII MoAb. Furthermore, labeling of 
LC with FITC-conjugated al1ti-FcyR MoAb and immunoprecipita-
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tion of LC protein extracts with various MoAb confirmed the pres-
ence ofFcyRll/CD32 and showed no detectable FcyRI and FcyRIll. 
However, this study also revealed that the expression of FcyRll at 
the LC surface was not stable. Indeed, after 24 to 48 h of culture, 
human LC lose their FcyRII as revealed by flow cytometry. We 
therefore investigated whether the disappearance of the membrane-
associated FcyRII was due to a modification in its recycling pathway 
or resulted from a proteolytic cleavage of the receptor at the cell 
surface. Such proteolysis of FcyRII has been previously observed at 
the cell surface of mouse L cells transfected with a murine P1 FcyRII 
cDNA [5], resulting in the appearance of soluble forms of FcyRII in 
the cell-culture supernatants, corresponding to the extracellular 
portion of the receptor. Likewise, this mechanism seems to be also 
involved in the production of soluble FcyRII molecules by activated 
human B lymphocytes [6]. 
LOSS OF FcyRll/CD32 EXPRESSION BY CULTURED 
HUMAN LANGERHANS CELLS IS ACCOMPANIED BY 
THE APPEARANCE OF SOLUBLE 
FcyRll/CD32 MOLECULES 
In order to investigate the mechanism(s) underlying the disappear-
ance of FcyRII/CD32 from the LC surface, epidermal cell suspen-
sions, LC-enriched, and LC-depleted human epidermal cells were 
cultured for 24 h, at 37"C, in serum-free medium. The membrane 
FcyRll/CD32 expression was evaluated at several times by double 
immunolabeling (CD1a and CD32) techniques, whereas the pres-
ence of soluble CD32 molecules in cell-culture supernatants was 
concomitantly analyzed using a direct dot-blot assay with the 1251_ 
labeled anti-CD32 MoAb, IV.3. We observed that increasing 
amounts of soluble FcyRII/CD32 accumulated in the cell-culture 
supernatants whereas the FcyRII/CD32 expression decreased at the 
LC surface during culture. The concentration of soluble CD32 
molecules increased during the first 3 h of culture and decreased 
thereafter up to 24 h of culture. These soluble CD32 molecules 
were observed in supernatants of LC isolated by the immunomag-
netic bead technique, but could not be detected in supernatants of 
LC-depleted epidermal cells. Thus, we concluded that soluble 
CD32 molecules are produced by LC and appear concomitantly 
with the disappearance of FcyRII/CD32 molecules from the LC 
surface. 
The simultaneity between the disappearance of CD32 molecules 
from the LC surface and the appearance in the medium of soluble 
CD32 molecules suggested that CD32 molecules are released from 
LC surface by a proteolytic mechanism that affects membrane 
FcyRII/CD32. However, soluble FcyRII/CD32 may also be syn-
thesized by translation of an alternatively spliced transcript of 
FcyRII [7] that encodes for a hydrophilic molecule containing the 
extracellular and intracytoplasmic domains of the FcyRII but not 
the transmembrane domain. Such a mRNA is likely to encode a 
secreted soluble form of FcyRII/CD32, although there is at present 
no evidence for the existence of this protein. Hence, we first inves-
tigated whether LC produce a transmembrane domain deleted 
FcyRll/CD32 mRNA. 
HUMAN EPIDERMAL LANGERHANS CELLS PRODUCE 
A TRANSMEMBRANE-DOMAIN - DELETED 
FcyRllA mRNA 
In humans, at least three genes (named IIA, lIB, and lIe) encode 
FcyRII/CD32 [1] . The proteins encoded by the IIA and IIC genes 
differ mainly in their signal peptides; thus, the FcyRIIA and 
FcyRIIC are very similar. The FcyRllB differs primarily from the 
two other forms by its cytoplasmic tail. Furthermore, due to multi-
ple splicing schemes?f the pre-mRNA, all these genes are likely to 
e~code several protems: at least two FcyRIIB (b1 and b2), which 
differ by the length of their cytoplasmic tail, and two FcyRIIA 
which differ by the presence or absence of the transmembrane do~ 
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main. However, although the FcyRIIA membrane-associated form 
is expressed at the cell surface, the soluble protein corresponding to 
the transmembrane-domain - deleted FcyRllA has not yet been 
clearly identified in vivo or in vitro. 
In order to detect the presence in LC of a possible 
transmembrane-domain-deleted FcyRIIA mRNA, total RNA of 
freshly isolated LC and of cultured LC was isolated by the guani-
dium isothiocyanate method. Amplification of reverse transcribed 
RNA by polymerase chain reaction (RT -PCR) was performed using 
two oligonucleotides specific for the extracellular and the cytoplas-
mic domain of the FcyRIIA, thus amplifying a fragment spanning 
the transmembrane domain. Two cDNA fragments of approxi-
mately 500 and 350 bp long were observed. Cloning and sequenc-
ing of these two fragments confirmed that both fragments encode 
for FcyRIIA and revealed that they differed by a 123-bp deletion 
corresponding to the transmembrane coding region (Fig 1). Thus, 
LC are likely to produce both the membrane-associated form and 
the soluble secreted form of FcyRIIA. 
TN Fa MODULATES THE EXPRESSION OF THE 
MEMBRANE ASSOCIATED FORM :AND OF THE 
SOLUBLE SECRETED FORM OF FcyRIl/CD32 IN 
CULTURED HUMAN LANGERHANS CELLS 
In order to improve LC viability, we then added human recombi-
nant TN Fa (10 ng/ml) to epidermal cell-culture medium. 111 these 
conditions,little variation in the expression ofFcyRll/CD32 on the 
LC surface was observed during the first 24 h of culture. However, 
the direct dot-blot assay with the 1251-labeled MoAb anti-CD32, 
IV.3, showed the presence of soluble FcyRll/CD32 molecules in 
the culture supernatants after 1, 3, 6, and 18 h of culture. Moreover, 
RT-PCR performed on the TN Fa-treated LC indicated that the 
presence of TN Fa in the culture medium provoked an increase in 
the amount of transmembrane-deleted mRN A within the first hour 
of culture. This mRNA predominated over the membrane form, 
cnc~ding mRNA after 3, 6, and 24 h of culture. Densitometry 
studies performed on the two PCR products revealed that the ratio 
between the mRNA encoding the membrane-associated form and 
the mRNA encoding the soluble-secreted form decreased from 1.5 
in freshly isolated LC to.O.6 in LC cultured for 24 h in the presence 
of TNFa. However, thiS study allowed only a relative quantifica-
tion between the two forms. 
CONCLUSION AND PROSPECTS 
In conclusion, our results show that LC express at least the FcyRlIA 
gene, and prel~minary results from our laboratory suggest that the 
FcyRIIB gene IS also transcribed, indicating that LC resemble mon-
ocytes and macrophages as far as FcyRll expression is concerned [1]. 
Two transcripts derived from the IlA gene have been observed: one 
mRNA encodes fo~ a membrane-associated receptor whereas an-
other mRNA, lackmg the transmembrane-domain-encoding se-
quence, is likely to generate a soluble-secreted form. These two 
transcripts ~an be detected in sheets of epidermis obtained from 
healthy patients at ratios similar to those observed in purified fresh 
LC. Thus, the procedure of purification of LC does not seem to 
affect our results. The biosynthesis of both forms of FcyRIIA 
mRNA appears to be regulated by TNFa, which apparently stimu-
lates the production of the transmembrane-deleted mRN A. Because 
soluble FcyRIl/CD32 are released from cultured LC, our results 
strongly suggest that the secretion of a soluble CD32 molecule 
accounts for at least a part of the release of CD32 into the culture 
medium, whereas some of these molecules could also result from a 
proteolytic c.leav~ge o~ the cell-surface receptor. 
A~ shown m tlllS reView, many questions still remain unsolved. In 
particular, the mechanisms leading to the release by LC of soluble 
FcyRIl/CD32 molecules have to be detailed. Also, it is unclear 
whether there is an effective production and secretion by LC of the 
~ransmembr~ne-deleted form, resulting from the alternative splic-
mg of tl~e pnmary transcript ofFcyRIIA, and whether soluble forms 
also denve from proteolysis of the membrane receptor. The respec-
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Soluble FC'YRIIA mRNA 446 ________ CAAGCC _______ _ 930 
i re 1. Two fragments of FcyRIIA are obtained by RT-PC~ from total RNA of human epidermal Langerhans cells using two oligonucleotides flanking 
F gu nsmembrane domain of FcyRIlA. Cloning and sequencing of these two fragments revealed that they differed by a 123-bp deletion (opell triallgle) 
the traponding to the transmembrane coding region. Numbering is in accordance with Brooks et al [10}. 
corres 
. functions of the membrane forms of FcyRIIA and FcyRIIB 
n
ve in to be defined, notably with regard to their internalization in 
~~~y receptor-mediated endocytosis. Last, the role of the soluble 
CD32 molecules released by LC within the epidermis or elsewhere 
. tally unknown. Soluble proteins derived from membrane-asso-l~ ttO d receptors for the Fc fragment of immunoglobulins have been 
CIa e I II' / d d ribed for the ow-amlllty receptors FcyRIll CD16 an /~~I1/CD23 and their functions are still a subject of debate [8,9]. 
SCI hie CD32 could be involved in the regulation of LC "matura-
.0 u" and the cel lular processes that are dependent upon activation 
Urn, embrane CD32 (on LC, as well as on other cell types), and/or 
° ; act upon other cells that migrate in inflammatory skin such as T 
mall neutrophils, macrophages, and even keratinocytes. 
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